Updated project metadata. In this study, we screened a group of newly synthesized tyrosine kinase inhibitors, and discovered MZH29 was a potent FLT3 inhibitor. Remarkably, MZH29 is well tolerated and effective in the clinically known FLT3 mutants in the constructed BaF3 model cells. MZH29 could also lead to complete tumor regression in the mouse xenograft model and increases survival in the bone marrow engraftment model. Further proteomics study indicates that the inhibition effects of MZH29 and AC220 are in a similar manner. All the results present here support that MZH29 could be a promising candidate for both the FLT3 WT and drug resistance mutant AML.